These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9613918)

  • 1. Lipid-lowering therapy in low-risk patients.
    Pearson TA
    JAMA; 1998 May; 279(20):1659-61. PubMed ID: 9613918
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comment from the cardiologic viewpoint].
    Lüscher TF
    Praxis (Bern 1994); 2009 Feb; 98(3):129-30. PubMed ID: 19180438
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins for stroke: the second story?
    Plutzky J; Ridker PM
    Circulation; 2001 Jan; 103(3):348-50. PubMed ID: 11157683
    [No Abstract]   [Full Text] [Related]  

  • 4. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
    Rosenson RS; Tangney CC
    JAMA; 1998 May; 279(20):1643-50. PubMed ID: 9613915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?
    Kostapanos MS; Katsiki N; Elisaf MS; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Mar; 10(2):173-7. PubMed ID: 22250844
    [No Abstract]   [Full Text] [Related]  

  • 9. [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
    März W
    MMW Fortschr Med; 2003 Dec; 145(50):46-9. PubMed ID: 14963971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC; Wang HH; Liu KS
    Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract]   [Full Text] [Related]  

  • 13. All at sea: new lipid-lowering drug trials continue to disappoint.
    Wierzbicki AS
    Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total lipid management and residual risk: beyond statin therapy.
    Evans M
    Br J Hosp Med (Lond); 2011 Mar; 72(3):132-6. PubMed ID: 21475092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
    Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
    Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New European and American guidelines on the management of blood cholesterol : similarities and differences].
    Butty A; Rodondi N; Nanchen D
    Rev Med Suisse; 2020 Mar; 16(684):438-443. PubMed ID: 32134222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do patients on statins also need niacin?
    Jones KW
    JAAPA; 2013 Jul; 26(7):9-10. PubMed ID: 23923280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.